<code id='1CA830E86F'></code><style id='1CA830E86F'></style>
    • <acronym id='1CA830E86F'></acronym>
      <center id='1CA830E86F'><center id='1CA830E86F'><tfoot id='1CA830E86F'></tfoot></center><abbr id='1CA830E86F'><dir id='1CA830E86F'><tfoot id='1CA830E86F'></tfoot><noframes id='1CA830E86F'>

    • <optgroup id='1CA830E86F'><strike id='1CA830E86F'><sup id='1CA830E86F'></sup></strike><code id='1CA830E86F'></code></optgroup>
        1. <b id='1CA830E86F'><label id='1CA830E86F'><select id='1CA830E86F'><dt id='1CA830E86F'><span id='1CA830E86F'></span></dt></select></label></b><u id='1CA830E86F'></u>
          <i id='1CA830E86F'><strike id='1CA830E86F'><tt id='1CA830E86F'><pre id='1CA830E86F'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:1263
          Blood samples
          Marion Berard/AFP/GettyImages

          With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

          Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

          advertisement

          “There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc
          JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

          InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates

          read more
          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more

          It's time to retire 'poor historian' from clinicians' vocabularies

          AdobeShouldwepitythe“poorhistorians”—theindividualsorfamilymemberswhocan’tgiveaclearaccountingofthei